← Back to Clinical Trials
Recruiting NCT06633666

NCT06633666 Acupuncture for Post COVID-19 Condition (Long COVID) Neuropsychiatric Symptoms

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06633666
Status Recruiting
Phase
Sponsor Hong Kong Baptist University
Condition Long Covid19
Study Type INTERVENTIONAL
Enrollment 160 participants
Start Date 2023-07-30
Primary Completion 2026-01-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
Acupuncture

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 160 participants in total. It began in 2023-07-30 with a primary completion date of 2026-01-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

In this study, a 12-week pragmatic, randomized, double-blinded clinical trial will be conducted to evaluate the efficacy of acupuncture for the treatment of long Covid neuropsychiatric symptoms and provide reference for clinical non-drug treatment.

Eligibility Criteria

Inclusion Criteria: * meet the clinical diagnosis of Long COVID by the World Health Organization (WHO), with no neuropsychiatric symptoms 1 year before infection with Covid-19, and continue to have at least one neuropsychiatric symptom for 2 months after SARS-CoV-2 turned negative 3 months above; * aged 12 to 80 years; * willing and able to consent, and complete all assessment and study procedures Exclusion Criteria: * patients with a history of chronic neuropsychiatric symptoms; * cardiovascular diseases pre-existing to the Covid-19 episode such as arrhythmia, heart failure, myocardial infarction, and patients with cardiac pacemakers; * documented pre-existing history of psychiatric illness, including substance abuse; * suicidal tendencies (attempted suicide in the 12 months before the study); * any chronic or remote neurological disorder (i.e. stroke, head trauma, epilepsy, tumor); * those who participated in other clinical trials within one month; * pregnant or lactating female patients; * have surgery within two months before the study or will have a scheduled surgery during the study; * acute brain injury or acute encephalopathy from another etiology than Covid-19 (e.g., sepsis, liver or renal failure, alcohol or drug withdrawal, drug toxicity); * open-heart cardiac surgery or cardiac arrest during the last 6 months; * patients who received acupuncture treatment 1 month before the start of the study; * patients who were unable to complete the assessment during screening due to severe mental, cognitive, or emotional impairment

Contact & Investigator

Central Contact

Linda Zhong, MD., Ph.D

✉ ldzhong0305@gmail.com

📞 85234116523

Principal Investigator

Dong Jue Wei, MD.

STUDY CHAIR

Hong Kong Baptist University

Frequently Asked Questions

Who can join the NCT06633666 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Long Covid19. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06633666 currently recruiting?

Yes, NCT06633666 is actively recruiting participants. Contact the research team at ldzhong0305@gmail.com for enrollment information.

Where is the NCT06633666 trial being conducted?

This trial is being conducted at Kowloon Tong, Hong Kong.

Who is sponsoring the NCT06633666 clinical trial?

NCT06633666 is sponsored by Hong Kong Baptist University. The principal investigator is Dong Jue Wei, MD. at Hong Kong Baptist University. The trial plans to enroll 160 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology